Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

317 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study.
Passamonti F, Palandri F, Saydam G, Callum J, Devos T, Guglielmelli P, Vannucchi AM, Zor E, Zuurman M, Gilotti G, Zhang Y, Griesshammer M. Passamonti F, et al. Among authors: callum j. Lancet Haematol. 2022 Jul;9(7):e480-e492. doi: 10.1016/S2352-3026(22)00102-8. Epub 2022 May 18. Lancet Haematol. 2022. PMID: 35597252 Clinical Trial.
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.
Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, Callum J, Vannucchi AM, Sivgin S, Bensasson C, Khan M, Mounedji N, Saydam G. Passamonti F, et al. Among authors: callum j. Lancet Oncol. 2017 Jan;18(1):88-99. doi: 10.1016/S1470-2045(16)30558-7. Epub 2016 Dec 2. Lancet Oncol. 2017. PMID: 27916398 Clinical Trial.
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial.
Griesshammer M, Saydam G, Palandri F, Benevolo G, Egyed M, Callum J, Devos T, Sivgin S, Guglielmelli P, Bensasson C, Khan M, Ronco JP, Passamonti F. Griesshammer M, et al. Among authors: callum j. Ann Hematol. 2018 Sep;97(9):1591-1600. doi: 10.1007/s00277-018-3365-y. Epub 2018 May 27. Ann Hematol. 2018. PMID: 29804268 Free PMC article. Clinical Trial.
A retrospective observational study of leucoreductive strategies to manage patients with acute myeloid leukaemia presenting with hyperleucocytosis.
Kuo KH, Callum JL, Panzarella T, Jacks LM, Brandwein J, Crump M, Curtis JE, Gupta V, Lipton JH, Minden MD, Sher GD, Schimmer AD, Schuh AC, Yee KW, Keating A, Messner HA. Kuo KH, et al. Among authors: callum jl. Br J Haematol. 2015 Feb;168(3):384-94. doi: 10.1111/bjh.13146. Epub 2014 Oct 10. Br J Haematol. 2015. PMID: 25303497 Free article.
Hyperhemolysis associated with marginal zone lymphoma.
Yan M, Callum J, Lin Y. Yan M, et al. Among authors: callum j. Leuk Lymphoma. 2015 Mar;56(3):829-31. doi: 10.3109/10428194.2014.939969. Epub 2014 Aug 4. Leuk Lymphoma. 2015. PMID: 24991717 No abstract available.
Major haemorrhage: putting evidence into practice.
Callum J, Tresierra S, Woolley T. Callum J, et al. Br J Haematol. 2022 Aug;198(4):619-622. doi: 10.1111/bjh.18246. Epub 2022 Jun 10. Br J Haematol. 2022. PMID: 35687759 No abstract available.
Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial.
Stanworth SJ, Killick S, McQuilten ZK, Karakantza M, Weinkove R, Smethurst H, Pankhurst LA, Hodge RL, Hopkins V, Thomas HL, Deary AJ, Callum J, Lin Y, Wood EM, Buckstein R, Bowen D; REDDS Investigators. Stanworth SJ, et al. Among authors: callum j. Br J Haematol. 2020 Apr;189(2):279-290. doi: 10.1111/bjh.16347. Epub 2020 Jan 20. Br J Haematol. 2020. PMID: 31960409 Free article. Clinical Trial.
317 results